Mostrar el registro sencillo del ítem

Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study (Burkimab)

dc.contributor.authorRibera, Josep-María
dc.contributor.authorGarcia, Olga
dc.contributor.authorGrande, Carlos
dc.contributor.authorEsteve, Jordi
dc.contributor.authorOriol, Albert
dc.contributor.authorBergua, Juan
dc.contributor.authorGonzález-Campos, José
dc.contributor.authorVall-Llovera, Ferrán
dc.contributor.authorTormo, Mar
dc.contributor.authorHernandez-Rivas, Jesus María
dc.contributor.authorGarcía, Daniel
dc.contributor.authorBrunet, Salut
dc.contributor.authorAlonso, Natalia
dc.contributor.authorBarba, Pere
dc.contributor.authorMiralles, Pilar
dc.contributor.authorLlorente, Andreu
dc.contributor.authorMontesinos, Pau
dc.contributor.authorMoreno, María-José
dc.contributor.authorHernandez-Rivas, Jose Angel
dc.contributor.authorBernal, Teresa
dc.date.accessioned2025-01-31T07:34:02Z
dc.date.available2025-01-31T07:34:02Z
dc.date.issued2013-05-01
dc.identifier.citationCancer, 119(9), p. 1660-1668 (2013); doi:10.1002/cncr.27918
dc.identifier.urihttps://hdl.handle.net/10651/76404
dc.description.sponsorshipSupported in part by the grant RD12-0036-0029 from RTICC Instituto Carlos III, Spain.
dc.format.extentp. 1660-1668spa
dc.language.isospaspa
dc.relation.ispartofCancer 119(9)spa
dc.rights© 2013 American Cancer Society
dc.titleDose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study (Burkimab)spa
dc.typejournal articlespa
dc.identifier.doi10.1002/cncr.27918
dc.relation.projectIDRD12-0036-0029
dc.relation.publisherversionhttps://doi.org/10.1002/cncr.27918
dc.rights.accessRightsembargoed access
dc.type.hasVersionVoR


Ficheros en el ítem

untranslated

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem